a-2b干扰素治疗HBeAg阳性慢性乙型肝炎疗效及预测因素临床分析  

Clinical study of interferon-alpha 2b antiviral therapy for HBeAg positive chronic hepatitis B patients

作　　者：苏瑞霞[1] 

机构地区：[1]东南大学附属中大医院,江苏南京210009

出　　处：《中国中医药咨讯》2011年第4期34-35,共2页

摘　　要：目的观察普通a-2b干扰素和聚乙二醇干扰素（PEG—IFN）a-2b治疗HBeAg阳性慢性乙型肝炎的疗效及预测因素分析。方法选择HBeAg阳性慢性乙型肝炎患者60例，随机给予30例使用安达芬（安徽安科公司生产a-2b干扰素）500万单位，皮下注射，每周三次；30例给予Peg-IFNda-2b佩乐能（先灵葆雅公司生产聚乙二醇a-2b干扰素）1．0μg，kg皮下注射，每周一次。疗程均为52周，停药后随访24周。结果1．治疗结束和随访24周时，普通干扰素组与Peg-IFN组的完全应答率、部分应答率、无应答率及持续应答率均无统计学差异。2．普通干扰素组治疗早期ALT更易反弹，随访结束时两组ALT复常率无统计学差异。3．治疗第1～4周HBVDNA明显下降〉2Log及治疗过程中ALT急性反弹，能取得持久病毒学应答，复发率低。结论两种不同剂型的a-2b干扰素治疗HBeAg阳性慢性乙型肝炎的应答率相似，无显著性差异。快速病毒学应答及AIT急性反弹是干扰素疗效的有效预测因素。Objective To investigate the efficacy and prediction factors of IFN α -2b with PEG-IFN α -2b in treating HBeAg positive chronic hepatitis B patients. Methods sixty HBeAg positive chronic hepatitis B patients were enrolled into this study. The patients received IFN α -2b（groupA：5MU SC,three times a week） or PEG-IFN α -2b（group B： 1.0 μg/kg body weight, SC,once a week） for 52 weeks,and followed up for 24 weeks. Results 1. complete response, partial response, non-response and sustained response between the two groups had no statistically significance differences at the end of treatment and after follow-up. 2. ALT easier to rebound in IFN α -2b early antiviral treatment, yet normalization rate had no statistically significance differences after follow-up.3. HBV DNA〉2Log sharply declined in 1 -4 weeks, and ALT quick rebound within the course of treatment in patients, Sustained virological response can be achieved and relapse rate is low. Conclusions The efficacy seems to be Similar between the Two different formulations of interferon α -2b treatment for HBeAg positive chronic hepatitis B patients. Rapid virological response and ALT quick rebound are effective factors for predicting IFN α -2b therapy response In CHB patients.

关 键 词：HBEAG阳性慢性乙型肝炎 A-2B干扰素 治疗早期 预测因素 临床分析 疗效 聚乙二醇干扰素 ALT复常率 

分 类 号：R512.620.5[医药卫生—内科学]